Curaleaf Holdings - CEO, Joseph Lusardi
CEO, Joseph Lusardi
Source: The Green Fund
Market Herald logo


Be the first with the news that moves the market
  • Curaleaf Holdings (CSE:CURA) has been approved as a Clinical Registrant in the US state of Pennsylvania
  • The approval was issued by the Commonwealth’s Department of Health, Office of Medical Marijuana
  • Under the medical marijuana research program Curaleaf will be free to open a cultivation and processing facility, and up to six dispensaries
  • Shares in the company are currently down 0.88 per cent to C$7.91, with a market cap of C$3.73 billion

Curaleaf Holdings (CSE:CURA) has announced its approval as a Clinical Registrant in Pennsylvania.

The company is a multi-state cannabis operator, with operations on both the East and West coasts of the United States.

Issued by the Department of Health, the approval will allow Curaleaf to open a cultivation and processing facility, and up to six dispensaries in the state.

In turn, the company will support research initiatives via the provision of medical cannabis, general expertise and distribution to relevant patients.

“This research is essential to providing physicians with more evidence-based research to make clinical decisions for their patients,” said the Department of Health’s Dr. Rachel Levine.

“It is the cornerstone of our program and the key to our clinically based, patient- focused program for those suffering with cancer, PTSD and other serious medical conditions.”

Curaleaf currently operates 53 dispensaries in 14 US states, with 15 cultivation and 24 processing sites.

The company’s CEO, Joseph Lusardi, thanked the Pennsylvania Department of Health and confirmed the company’s commitment to research and medical patients.

“Curaleaf has always been focused on high-quality cannabis products, as well as superior patient care and education,” he said.

“We look forward to contributing to medical research that will ultimately benefit not only the residents of the Commonwealth, but the entire country.”

Shares in Curaleaf are currently down 0.88 per cent to C$7.91, with a market cap of C$3.73 billion.

More From The Market Herald

" Israeli Technology company BYND Cannasoft (CSE:BYND) acquires Zigi Carmel Investments Ltd.

BYND Cannasoft (BYND) closes the acquisition of Zigi Carmel Investments with a value of US $28 million.

" The Market Herald’s Weekly Cannabis Report – Sept 23, 2022

Cannara Biotech (TSXV:LOVE) has entered British Columbia’s marketplace and has launched its first two premium products in the vape and accessory categories.
The Gummy Project to serve Vancouvers Shakespeare Festival

" The Gummy Project (CSE:GUMY) expands in U.S. after receiving purchase order from a 5-star luxury hotel

The Gummy Project (GUMY) has received a purchase order from the 5-star luxury Four Seasons Hotel San Francisco.

" Nextleaf (CSE:OILS) launches new cannabis brand, High Plains

Nextleaf Solutions (OILS) has launched its new cannabis brand, High Plains.